CERTIFIED DATA SUMMARIES COULD BE POSSIBLE WITHOUT LEGISLATION, LASAGNA SUGGESTS AT HOUSE FDA OVERSIGHT HEARING; WAXMAN QUESTIONS NEED FOR BILL
FDA could accept certified data summaries for preclinical and clinical trials for NDAs without new enabling legislation, Tufts Center for the Study of Drug Development Director Louis Lasagna, PhD, testified at a hearing before the House Commerce/Oversight Subcommittee June 19.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth